Paradigm Asset Management’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Paradigm Asset Management’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-450	Closed	-$18K	–	815
2016 Q2	$18K	Hold	450	–	–	﹤0.01%	725
2016 Q1	$15.7K	Sell	450 -900	-67%	-$33K	﹤0.01%	769
2015 Q4	$58K	Buy	+1,350	New	+$67.6K	0.01%	615
2014 Q3	–	Sell	-18,600	Closed	-$501K	–	888
2014 Q2	$501K	Buy	18,600 +500	+3%	+$13K	0.07%	312
2014 Q1	$469K	Sell	18,100 -1,400	-7%	-$33.6K	0.06%	324
2013 Q4	$423K	Sell	19,500 -500	-3%	-$10.2K	0.06%	345
2013 Q3	$389K	Buy	+20,000	New	+$354K	0.06%	342

Other funds holding BSTC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RCMC

RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Paradigm Asset Management's BSTC Position: Q3 2016 in Review

Paradigm Asset Management sold out of BioSpecifics Technologies Corp. (BSTC) in Q3 2016, closing a stake of 450 shares — an estimated $18K sold.

Paradigm Asset Management first reported a position in BSTC in Q3 2013 and held it in 7 quarters. The position peaked at $501K in Q2 2014. 90 funds tracked by Wall St. Rank hold BSTC as of Q3 2016.

Paradigm Asset Management reported no remaining BioSpecifics Technologies Corp. position as of Q3 2016 after selling out during the quarter.
Paradigm Asset Management sold 450 BioSpecifics Technologies Corp. shares in Q3 2016, an estimated $18K.
Paradigm Asset Management first reported a position in BioSpecifics Technologies Corp. in Q3 2013 and held it in 7 quarters.
Paradigm Asset Management's BioSpecifics Technologies Corp. position peaked at $501K in Q2 2014.
90 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q3 2016.

Based on Paradigm Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.